PT Kalbe Farma Tbk (PTKFY)
17.03
0.00 (0.00%)
USD |
OTCM |
Jun 21, 16:00
PT Kalbe Farma Enterprise Value: 3.823B for June 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 21, 2024 | 3.823B |
| June 20, 2024 | 3.823B |
| June 18, 2024 | 3.823B |
| June 17, 2024 | 3.823B |
| June 14, 2024 | 3.823B |
| June 13, 2024 | 3.823B |
| June 12, 2024 | 3.823B |
| June 11, 2024 | 3.823B |
| June 10, 2024 | 3.823B |
| June 07, 2024 | 3.823B |
| June 06, 2024 | 3.823B |
| June 05, 2024 | 3.823B |
| June 04, 2024 | 3.823B |
| June 03, 2024 | 3.823B |
| May 31, 2024 | 3.823B |
| May 30, 2024 | 3.823B |
| May 29, 2024 | 3.823B |
| May 28, 2024 | 3.823B |
| May 24, 2024 | 3.823B |
| May 23, 2024 | 3.823B |
| May 22, 2024 | 3.823B |
| May 21, 2024 | 3.823B |
| May 20, 2024 | 3.823B |
| May 17, 2024 | 3.823B |
| May 16, 2024 | 3.823B |
| Date | Value |
|---|---|
| May 15, 2024 | 3.823B |
| May 14, 2024 | 3.823B |
| May 13, 2024 | 3.823B |
| May 10, 2024 | 3.823B |
| May 09, 2024 | 3.823B |
| May 08, 2024 | 3.823B |
| May 07, 2024 | 3.823B |
| May 06, 2024 | 3.823B |
| May 03, 2024 | 3.823B |
| May 02, 2024 | 3.823B |
| May 01, 2024 | 3.823B |
| April 30, 2024 | 3.823B |
| April 29, 2024 | 3.883B |
| April 26, 2024 | 6.614B |
| April 25, 2024 | 6.614B |
| April 24, 2024 | 6.614B |
| April 23, 2024 | 6.614B |
| April 22, 2024 | 6.614B |
| April 19, 2024 | 6.614B |
| April 18, 2024 | 6.614B |
| April 17, 2024 | 6.614B |
| April 16, 2024 | 6.614B |
| April 15, 2024 | 6.614B |
| April 12, 2024 | 6.614B |
| April 11, 2024 | 6.614B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.405B
Minimum
Mar 31 2020
6.804B
Maximum
Feb 16 2023
5.347B
Average
5.029B
Median
Aug 27 2020
Enterprise Value Benchmarks
| Taihe Group Inc | -- |
| CEL-SCI Corp | 64.56M |
| AIM ImmunoTech Inc | 13.37M |
| IGC Pharma Inc | 33.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 61.09M |
| Revenue (Quarterly) | 533.54M |
| Total Expenses (Quarterly) | 455.56M |
| EPS Diluted (Quarterly) | 0.2641 |
| Gross Profit Margin (Quarterly) | 39.71% |
| Profit Margin (Quarterly) | 11.45% |
| Earnings Yield | 4.72% |
| Operating Earnings Yield | 6.13% |
| Normalized Earnings Yield | 4.721 |